(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 26.34% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Zymeworks's revenue in 2025 is $93,384,000.On average, 5 Wall Street analysts forecast ZYME's revenue for 2025 to be $6,971,554,641, with the lowest ZYME revenue forecast at $3,693,225,076, and the highest ZYME revenue forecast at $9,832,340,721. On average, 5 Wall Street analysts forecast ZYME's revenue for 2026 to be $12,649,504,936, with the lowest ZYME revenue forecast at $6,721,669,638, and the highest ZYME revenue forecast at $21,829,747,539.
In 2027, ZYME is forecast to generate $11,389,488,033 in revenue, with the lowest revenue forecast at $4,668,793,964 and the highest revenue forecast at $14,963,833,072.